424 related articles for article (PubMed ID: 7973038)
21. Clinical value of neuron specific enolase and tissue polipeptidic antigen for the management of patients with lung cancer.
Spinazzi A; Soresi E; Borghini U; Boffi R; Vigorelli R; Scoccia S
J Nucl Med Allied Sci; 1990; 34(4 Suppl):141-5. PubMed ID: 1965446
[No Abstract] [Full Text] [Related]
22. [Diagnostic usefulness of the determination of serum neuron-specific enolase in small cell bronchial carcinoma].
Romero S; Padilla I; Mauri M; García-Sevila R; Martín C; Pérez-Carbonell A
Med Clin (Barc); 1990 Jun; 95(1):10-4. PubMed ID: 2172670
[TBL] [Abstract][Full Text] [Related]
23. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
24. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
Wu Y; Wu Y; Wang L; Qu L
Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
[TBL] [Abstract][Full Text] [Related]
25. [Update regarding the role of biomarkers in early diagnosis of non-small cell bronchopulmonary cancer].
Dragomir A; Moldoveanu E; Mihălţan F
Pneumologia; 2011; 60(1):7, 9-13. PubMed ID: 21548194
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
27. [Determination of various tumor markers, with special reference to neuron-specific enolase in lung cancer].
Yano H; Hino M; Nishiwaki Y; Kodama T; Hayashibe A; Kudo H; Inoue Y; Nishiyama Y; Sone Y; Oshima T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):77-83. PubMed ID: 3026257
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
[TBL] [Abstract][Full Text] [Related]
29. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
[TBL] [Abstract][Full Text] [Related]
30. [Ca 19-9 and Ca 50 in the diagnosis of bronchial carcinoma: comparison with CEA].
Pecchio F; Rapellino M; Oliaro A; Moscato D; Adamo R; Albertino B; Lo Faso C; Faga C; Borasio P
Minerva Med; 1988 Mar; 79(3):183-6. PubMed ID: 2834670
[TBL] [Abstract][Full Text] [Related]
31. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
32. [Tumor markers used in diagnosis and monitoring of primary bronchopulmonary carcinoma].
Mahler B
Pneumologia; 2008; 57(3):175-7. PubMed ID: 18998332
[TBL] [Abstract][Full Text] [Related]
33. Tissue polypeptide antigen in bronchogenic carcinoma.
Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O
Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159
[TBL] [Abstract][Full Text] [Related]
34. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
35. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
36. [Tumor markers. II. Their significance in the follow-up of patients after radical resection of lung neoplasms].
Ratto GB; Capponi G; De Grandi R; Augeri C; Secco GB; Fardelli R
Minerva Chir; 1990 Oct; 45(20):1273-80. PubMed ID: 2082204
[TBL] [Abstract][Full Text] [Related]
37. [Significance of neuron-specific enolase (NSE) in the diagnosis of bronchial carcinomas and neuroendocrine tumors].
Fischbach W; Jany B; Nelkenstock R
Dtsch Med Wochenschr; 1986 Nov; 111(45):1721-5. PubMed ID: 3023003
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
39. Multiple sequential biomarkers in monitoring patients with carcinoma of the lung.
Aroney RS; Dermody WC; Aldenderfer P; Parsons P; McNitt K; Marangos PJ; Whitacre MY; Ruddon RW; Wiernik PH; Aisner J
Cancer Treat Rep; 1984 Jun; 68(6):859-66. PubMed ID: 6329508
[TBL] [Abstract][Full Text] [Related]
40. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
